USD10
ABUS azioni
Informazioni su Arbutus BiopharmaArbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
USD10
ABUS azioni
Informazioni su Arbutus BiopharmaArbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
23 mar at 13:30 GMT+0
Capitalizzazione di mercato
826,90 Mln USD
PREZZO DI APERTURA
Dati insufficienti
MINIMO (1 anno)
2,71 USD
MASSIMO (1 anno)
5,10 USD
MINIMO (24H)
Dati insufficienti
MASSIMO (24 ore)
Dati insufficienti
VOLUME (24 ore)
Dati insufficienti
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | Dati insufficienti | Dati insufficienti |
1 giorno | 4,24 USD | |
1 settimana | 4,30 USD | |
1 mese | 4,37 USD | |
1 anno | 3,39 USD |